Valuation : Biocorrx Inc

Market Cap 6.25M 5.39M 5.07M 4.62M 8.69M 593M 8.73M 59.95M 23.33M 302M 23.46M 22.95M 1B P/E 2024
-0.78x
P/E 2025 -1.56x
Enterprise Value 8.25M 7.12M 6.69M 6.1M 11.47M 783M 11.53M 79.14M 30.8M 398M 30.98M 30.31M 1.32B EV / Sales 2024
1,004x
EV / Sales 2025 11.4x
Free-Float
40.09%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 58 2020-11-08
President 77 2024-01-04
Director TitleAgeSince
Director/Board Member 58 2013-03-06
Chairman 57 -
Director/Board Member 77 2019-02-28
Change 5-day change 1-year change 3-year change Capi.($)
-15.84%+6.09% - - 6.25M
+3.18%+4.13%+30.56%+47.30% 120B
+0.72%-2.53%+2.90%+48.82% 89.73B
-2.66%-0.40%-1.20%+54.86% 29.6B
-0.97%-2.60%+33.12%+82.26% 26.52B
+0.90%-1.26%-2.53%-3.29% 21.71B
+0.58%-1.48%+44.51%+240.34% 21.41B
+3.61%+0.83%-7.01%+26.02% 14.81B
+0.23%-2.03%-10.22%-10.99% 12.14B
+0.52%-0.43%+29.27%+71.90% 11.22B
Average -1.04%-0.94%+13.27%+61.91% 38.58B
Weighted average by Cap. +1.22%-1.39%+16.62%+57.60%

Financials

2024 2025
Net sales 7.66K 6.61K 6.22K 5.67K 10.65K 727K 10.71K 73.53K 28.62K 370K 28.78K 28.15K 1.23M 797K 688K 647K 589K 1.11M 75.66M 1.11M 7.65M 2.98M 38.49M 2.99M 2.93M 128M
Net income -5.11M -4.4M -4.14M -3.77M -7.1M -485M -7.14M -48.98M -19.06M -247M -19.17M -18.76M -817M -3.44M -2.97M -2.79M -2.54M -4.78M -326M -4.81M -33M -12.84M -166M -12.92M -12.64M -551M
Net Debt 2.72M 2.34M 2.21M 2.01M 3.78M 258M 3.8M 26.08M 10.15M 131M 10.21M 9.98M 435M 2M 1.73M 1.62M 1.48M 2.78M 190M 2.8M 19.2M 7.47M 96.62M 7.51M 7.35M 320M
Logo Biocorrx Inc
BioCorRx Inc. is an addiction treatment solutions company. The Company is engaged in offering treatment for substance use and other related disorders. Its Beat Addiction Recovery is a substance use disorder recovery program that typically includes its Cognitive Behavioral Therapy (CBT) modules along with peer support via mobile app, along with medication prescribed by an independent treating physician under their discretion. The UnCraveRx Weight Loss Program is also a medication-assisted weight-loss program that includes access to concierge on-demand wellness specialists, nutritionists, fitness experts, and personal support from behavioral experts. It also controls BioCorRx Pharmaceuticals Inc., a clinical-stage drug development subsidiary, which is seeking FDA approval for BICX104, an implantable naltrexone pellet for the treatment of alcohol and opioid use disorders. It is also engaged in the establishment of alcoholism and opioid addiction rehabilitation and treatment centers.
Employees
-